Description

Overview

LL-37 is the 37-amino-acid active peptide generated from the human cathelicidin precursor hCAP18. It is a major component of innate host defense and has been studied for direct antimicrobial activity, biofilm interactions, endotoxin binding, immune-cell signaling, angiogenesis, and wound response. LL-37 biology is complex: depending on concentration and tissue context, it can be protective, inflammatory, or dysregulated. Apex should avoid presenting it as a simple broad-spectrum “infection treatment.”

How It Works

• Membrane disruption: LL-37 can interact with microbial membranes and alter membrane integrity in experimental systems.
• Immune modulation: It influences chemotaxis, cytokine signaling, and innate/adaptive immune responses.
• Wound biology: Research has examined angiogenesis, re-epithelialization, and tissue repair.

Research Areas

• Host-defense peptide biology
• Biofilm research
• Wound and skin biology
• Immune signaling

Research / Study Context

• Microbiology studies: In vitro work tests antimicrobial and biofilm endpoints across bacteria, fungi, and viruses.
• Cell and tissue models: Studies evaluate immune signaling, epithelial response, angiogenesis, and wound closure.

Key Research Findings

• LL-37 has broad biological activity beyond direct antimicrobial effects.
• Activity is strongly dependent on concentration and biological context.
• Therapeutic claims require caution because dysregulated LL-37 is also associated with inflammatory disease states.

Related Research

• Thymosin Alpha-1
• KPV
• BPC-157

Scientific Reference Starter Set

• Peptide Education Hub: LL-37 profile
• PubMed search: LL-37 cathelicidin host defense peptide
• PubMed search: LL-37 biofilm wound healing